Key Points

  • Mastercard said Monday in a statement on its website that Sachin Mehra, its long-time chief financial officer, has informed the board and colleagues that he will undergo treatment for non-Hodgkin lymphoma. The statement also said he will work remotely in the coming months and "remain actively engaged in day-to-day operations."
  • The company said: "The condition was detected very early, and scans and biopsies show it is highly localized and curable. Under the recommended treatment plan, Sachin's long-term prognosis is excellent." A Mastercard spokesperson declined to comment beyond the statement.
  • Mehra has served as CFO since 2019 and has worked at Mastercard, headquartered in Purchase, New York, for 14 years. According to his LinkedIn profile, he previously held senior finance roles at other public companies. Before joining Mastercard, he was vice president and treasurer at energy company Hess, and earlier served as managing director of the New York treasury office at General Motors.

In-Depth Analysis

Mastercard's handling of its finance chief's health condition has drawn high praise from some corporate governance experts. They believe that disclosing an executive's medical issues is often a delicate task.

First, the company must determine whether the matter is material to the company; if so, it must keep investors informed while protecting the executive's privacy.

"The CFO is essentially the company's face on Wall Street," said Charles Elson, founding director of the Weinberg Center for Corporate Governance at the University of Delaware, making their presence critical. "When there is uncertainty, it should be disclosed... They made the right decision."

Medical issues often pose challenges for companies because they must "balance transparency, oversharing, and confidentiality, especially when making any executive disclosure," said Shawn Cole, president of executive search firm Cowen Partners, in an email response.

In cases where the CFO may be unable to perform duties, the board must develop a plan to cover financial oversight, auditing, and strategic planning, while also managing communications around the disclosure.

Cole noted that if disclosure is insufficient and the issue escalates—such as the CFO leaving due to health problems or the company suffering losses—it could trigger investor surprise and concern. Conversely, if the company "overshares" and it turns out not to be a big deal, it could invite unnecessary scrutiny. But he praised Mastercard for carefully calibrating its disclosure.

"They managed to provide enough information to reassure stakeholders while avoiding unnecessary details," he said.

This issue has troubled some large public companies. For example, Apple CEO Steve Jobs resigned in 2011 saying "the day has come," stating he could no longer fulfill his duties after battling a rare form of pancreatic cancer, ABC News reported at the time. Earlier that year, debates raged over how much investors were entitled to know about his health, according to a 2011 article in The Atlantic. Jobs died in October 2011 at age 56, The New York Times reported.

Non-Hodgkin lymphoma, which Mehra faces, typically begins in white blood cells—part of the body's immune system, according to the American Cancer Society. It accounts for about 4% of cancer cases in the U.S. and can be detected early through common symptoms such as swollen lymph nodes.

Mastercard's disclosure comes just days after the company agreed to acquire cybersecurity firm Recorded Future for $2.65 billion, Payments Dive, a sister publication of Industry Dive, reported.

According to a company filing in April, Mehra's total compensation last year was $10.8 million, primarily consisting of $6.5 million in stock awards, $1.78 million in non-equity incentive plan compensation, $1.7 million in option awards, and a salary of $791,667.

Editor's note: This story has been updated with a photo.